Fiasp - a new, ultra-fast acting mealtime insulin
Canada first country to launch Fiasp.
Novo Nordisk has announced that Fiasp, a new, fast-acting mealtime insulin for the treatment of diabetes in adults, has been launched in Canada, following the recent marketing authorisation from Health Canada on 6 January 2017.
Fiasp is insulin aspart in an innovative formulation that more closely matches the natural physiological insulin response of a person without diabetes after a meal, compared with NovoRapid (conventional insulin aspart). Fiasp also has the option of a flexible dosing regimen (up to 20 minutes after starting a meal), without compromising overall glycaemic control, when compared to NovoRapid dosed at mealtime.
"The launch of Fiasp in Canada represents the first new mealtime insulin in 10 years. We hope to make this innovation available to as many people with diabetes as possible worldwide," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "The goal of any insulin treatment is to match the natural physiological insulin production we see in people without diabetes, both in speed and glycaemic control. Fiasp has narrowed the existing gap, getting us closer to that goal."
Fiasp is absorbed faster than NovoRapid, appearing twice as fast in the bloodstream after injection, which leads to improved glycaemic control after a meal. In clinical trials, Fiasp demonstrated improved overall glycaemic control in type 1 diabetes2 and comparable overall glycaemic control in type 2 diabetes, versus NovoRapid. Results also showed improved mealtime glucose control in type 1 and type 2 diabetes. This was achieved without a significant difference in the overall rate of severe or confirmed hypoglycaemia, compared with NovoRapid.
Clinical trial results showed that the faster absorption of Fiasp, compared to NovoRapid®, was even more pronounced in those using a continuous subcutaneous insulin infusion (CSII) system (insulin pump therapy). In addition, when compared with NovoRapid in a CSII setting in people with type 1 diabetes, Fiasp showed no difference in pump compatibility as assessed by microscopically confirmed infusion-set occlusions, and the treatments were equally effective in controlling glucose levels, compared to NovoRapid.
“People living with diabetes often struggle to control blood glucose around mealtimes, which can be extremely challenging and result in debilitating diabetes-related complications,” said Dr Rémi Rabasa-Lhoret, endocrinologist at the Institut de Recherches Cliniques de Montréal and onset 1 investigator. “With the approval of a faster-acting insulin, one that is closer to the natural physiological insulin response of a person without diabetes, we can further support people in managing their blood glucose levels around meals, which may help prevent hyperglycaemia, for instance, a condition that can cause serious complications for people living with diabetes.”
Following the first country launch in Canada, Fiasp will also be available in a number of European markets in the coming months.
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance